Cargando…

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Resistance to endocrine treatment occurs in ~30% of ER(+) breast cancer patients resulting in ~40,000 deaths/year in the USA. Preclinical studies strongly implicate activation of growth factor receptor, HER2 in endocrine treatment resistance. However, clinical trials of pan-HER inhibitors in ER(+)/H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Punturi, Nindo B., Seker, Sinem, Devarakonda, Vaishnavi, Mazumder, Aloran, Kalra, Rashi, Chen, Ching Hui, Li, Shunqiang, Primeau, Tina, Ellis, Matthew J., Kavuri, Shyam M., Haricharan, Svasti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134423/ https://www.ncbi.nlm.nih.gov/pubmed/34011995 http://dx.doi.org/10.1038/s41467-021-23271-0

Ejemplares similares

The uncharted role of HER2 mutant alleles in breast cancer
por: Kalra, Rashi, et al.
Publicado: (2023)

Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness
por: Oropeza, Elena, et al.
Publicado: (2023)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer
por: Lovejoy, Leann A., et al.
Publicado: (2023)

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
por: Kalra, Rashi, et al.
Publicado: (2022)

The DNA damage repair landscape in Black women with breast cancer
por: Mazumder, Aloran, et al.
Publicado: (2022)

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
por: Haricharan, Svasti, et al.
Publicado: (2017)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers
por: Venetis, Konstantinos, et al.
Publicado: (2020)

Dual HER2 blockade: preclinical and clinical data
por: Patel, Tejal A, et al.
Publicado: (2014)

Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade
por: Singh, Rohit, et al.
Publicado: (2013)

Emerging target discovery and drug repurposing opportunities in chordoma
por: Freed, Daniel M., et al.
Publicado: (2022)

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
por: Wang, Chaokun, et al.
Publicado: (2020)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
por: Batalha, Sofia, et al.
Publicado: (2023)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020)

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma
por: Catenacci, D.V.T., et al.
Publicado: (2021)

Erratum to: Dual HER2 blockade: preclinical and clinical data
por: Patel, Tejal A, et al.
Publicado: (2014)

HER2 Overexpression and Mismatch Repair Deficiency are Correlated with Malignancy in Colorectal Cancer
por: Luo, Hai, et al.
Publicado: (2021)

Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma
por: Sung, You-Na, et al.
Publicado: (2021)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
por: Tokunaga, Eriko, et al.
Publicado: (2021)

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
por: de Azambuja, E., et al.
Publicado: (2023)

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
por: Lin, Binwei, et al.
Publicado: (2023)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
por: Sajjadi, Elham, et al.
Publicado: (2021)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
por: Yang, Xue, et al.
Publicado: (2023)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
por: Candas-Green, Demet, et al.
Publicado: (2020)

The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
por: Pop, Lucian, et al.
Publicado: (2019)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2023)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m6qipmetts70ps4mf54uo6av7c